---
title: "安徽万邦医药科技股份有限公司 (301520.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301520.SZ.md"
symbol: "301520.SZ"
name: "安徽万邦医药科技股份有限公司"
industry: "生命科学工具与服务"
---

# 安徽万邦医药科技股份有限公司 (301520.SZ)

| Item | Detail |
|------|--------|
| Industry | 生命科学工具与服务 |
| Location | 沪深市场 |
| Website | [www.ahwbyy.cn](https://www.ahwbyy.cn) |

## Company Profile

公司 2006 年成立于合肥，全流程医疗健康 CRO 服务平台。公司将持续秉承用专注铸就专业，以专心秉承初心;专注研发，守护人类健康。公司是一家同时提供药学研究和临床研究服务的综合型 CRO 企业，通过合同形式为医药企业和其他医药研发机构提供专业化医药研发外包服务。公司拥有片剂、胶囊、肠溶制剂、口崩片、干混悬剂、咀嚼片、控释片、脂肪乳、凝胶贴膏、滴剂、注射液等多种剂型。公司自成立以来，荣获了合肥市知识产权示范企业、服务业规上企业、中国医药外包公司 20 强、共青团合肥市青年文明号、中华全国工商业联合会医药业商会星级理事单位、2018 年 “突出贡献奖—高成长优质奖” 等多个荣誉。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-22T04:30:09.000Z

**Overall: C (0.56)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 21 / 27 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.16% |  |
| Net Profit YoY | -62.38% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.96 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.97B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 295.23M |  |


**Multi Score**: C

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.70% | C |
| Profit Margin | 13.84% | B |
| Gross Margin | 20.33% | D |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -25.16% | E |
| Net Profit YoY | -62.38% | D |
| Total Assets YoY | -0.54% | D |
| Net Assets YoY | 0.28% | C |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 722.78% | B |
| OCF YoY | -25.16% | E |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.19 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 4.93% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 安徽万邦医药科技股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.70%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "13.84%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "20.33%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-25.16%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-62.38%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-0.54%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.28%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "722.78%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-25.16%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "4.93%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 药明康德 (SH.603259) | A | A | C | B | B | B |
| 02 | 康龙化成 (SZ.300759) | B | B | C | C | B | B |
| 03 | 皓元医药 (SH.688131) | B | A | C | C | B | B |
| 04 | 成都先导 (SH.688222) | B | B | D | B | B | B |
| 05 | 赛分科技 (SH.688758) | C | B | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 72.75 | 11/27 | 68.72 | 47.78 | 37.06 |
| PB | 1.96 | 2/27 | 1.98 | 1.87 | 1.77 |
| PS (TTM) | 10.07 | 22/27 | 9.51 | 8.54 | 7.17 |
| Dividend Yield | 0.00% | - | 2.07% | 0.84% | 0.79% |

## References

- [Company Overview](https://longbridge.com/en/quote/301520.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301520.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301520.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.